Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2013 by Jiangsu HengRui Medicine Co., Ltd..
Recruitment status was:  Active, not recruiting
Sponsor:
Information provided by (Responsible Party):
Jiangsu HengRui Medicine Co., Ltd.
ClinicalTrials.gov Identifier:
NCT01503502
First received: January 1, 2012
Last updated: April 9, 2013
Last verified: April 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2014
  Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)